Key result
Baloxavir marboxil presents a similar safety and efficacy profile to existing antiviral drugs used in the treatment of influenza A and B.
Why the study?
Flu is a serious medical and economic problem without satisfactory therapies, and baloxavir marboxil recently emerged as a therapy with a new mechanism of action.
What are the mechanisms, indications, effectiveness, and safety profiles of available antiviral drugs for influenza A and B?
What are the mechanisms, indications, effectiveness, and safety profiles of available antiviral drugs for influenza A and B?
Baloxavir marboxil offers a new mechanism of action with similar safety and efficacy to existing influenza treatments, highlighting the potential for future combination therapies.
May expand influenza antiviral options with baloxavir; leaves open comparative efficacy and resistance data.
Flu is a serious health, medical, and economic problem, but no therapy is yet available that has satisfactory results and reduces the occurrence of these problems. Nearly 20 years after the registration of the previous therapy, baloxavir marboxil, a drug with a new mechanism of action, recently appeared on the market. This is a promising step in the fight against the influenza virus. This article presents the possibilities of using all available antiviral drugs specific for influenza A and B. We compare all currently recommended anti-influenza medications, considering their mechanisms of action, administration, indications, target groups, effectiveness, and safety profiles. We demonstrate that baloxavir marboxil presents a similar safety and efficacy profile to those of drugs already used in the treatment of influenza. Further research on combination therapy is highly recommended and may have promising results.
No takes yet. Share an insight, caveat, or question.
Świerczyńska et al. (2022) conducted a review in Influenza A and B. Baloxavir marboxil and other antiviral drugs vs. Other anti-influenza medications was evaluated. Baloxavir marboxil presents a similar safety and efficacy profile to existing antiviral drugs used in the treatment of influenza A and B.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: